Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Status: Completed

Conditions: Liver Steatoses

Treatments: Diagnostic Test: USG, blood tests, waist, hip, height and blood pressure measurements

Study type: Interventional

Funder types: Other

Identifiers

NCT06443723

CholecystectomyMAFLD

Details and patient eligibility

About

The aim of this study was to examine the association between metabolic associated fatty liver disease (MAFLD) in participants who had undergone cholecystectomy and those who had not undergone cholecystectomy. MAFLD is defined as hepatic steatosis(with ultrasonography) entity in addition to the presence of overweight or obesity, diabetes mellitus, or evidence of metabolic dysfunction.

In this way, the long-term effects of cholecystectomy surgeries, which are commonly performed in the society and thought to be harmless, will be evaluated.

Full description

Cholecystectomy is known to be a harmless operation with low perioperative mortality and morbidity. However, the unexplained increase in metabolic disorders in cholecystectomy patients has led to the need for further investigation of cholecystectomy patients. Non-alcoholic fatty liver disease is an important health problem with an average prevalence of 25% worldwide and serious hepatic and systemic complications. The aim of this study was to examine the association of cholecystectomy with metabolic dysfunction associated fatty liver disease (MAFLD), which is an important public health problem in the long-term.

This case-controlled cross-sectional study was planned to evaluate the relationship between patients who had undergone cholecystectomy with MAFLD. MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, diabetes mellitus, or evidence of metabolic dysfunction.

The study included 86 participants with cholecystectomy and 63 participants without cholecystectomy. It was planned to compare the participants according to the diagnostic criteria for MAFLD (with or without MAFLD).

Enrollment: 149 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• who were found to have undergone cholecystectomy at least five years ago,
• who could feed orally and perform activities of daily living
• participants who had not undergone cholecystectomy with similar characteristics were included in the study

Exclusion criteria

• those with chronic liver disease
• malignancy or history of malignancy
• in a chemotherapy program
• with active infection
• any organ failure
• pregnancy
• use of drugs that cause steatosis in the liver

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

149 participants in 2 patient groups

cholecystectomy

Experimental group

Description:

Evaluation of hepatosteatosis by hepatobiliary ultrasonography in cholecystectomy patients. Height, hip, waist circumference, blood pressure measurement and hemogram, lipid parameters.

Treatment:

Diagnostic Test: USG, blood tests, waist, hip, height and blood pressure measurements

Control

Experimental group

Description:

Evaluation of hepatosteatosis by hepatobiliary ultrasonography in participants without cholecystectomy. Height, hip, waist circumference, blood pressure measurement and hemogram, lipid parameters.

Treatment:

Diagnostic Test: USG, blood tests, waist, hip, height and blood pressure measurements